MARIETTA, Ga., March 26, 2018 /PRNewswire/ — MiMedx Group, Inc. (NASDAQ: MDXG), a leading developer and marketer of regenerative and therapeutic biologics, today announced positive pain and foot function results from its Phase 2B clinical trial of AmnioFix® Injectable in the treatment of…
